Any current/future new fundraising through debt or equity?

After the recently completed rights issue, there are no further plans to raise additional capital through equity or debt at this time. (Page 13) The company aims to become debt-free by FY '29, targeting both long-term and working capital debt elimination. (Page 13) No major future fundraising activities for growth or debt paydown are expected in the next 2-3 years based on current plans. (Page 13)

Any current/future capex/capital investment/strategic investment?

No large greenfield capex planned; focus is on utilizing existing capacity (around 30% spare capacity available). Incremental capex being done to debottleneck lines for high-margin products and improve cycle times. No big capex projects; emphasis on "smart and wise" use of existing capacity. No current plans for additional capital raising beyond the recent rights issue; company aims to be debt-free by FY '29. Vizag facility mothballed; future use under strategic evaluation (options include potentially repositioning as multipurpose or high-potent API block). R&D investment of about INR 25 crore

Future growth expectations in sales/revenue/volumes?

The company expects growth momentum mainly from its base business, focusing on expanding existing products and customers rather than ibuprofen or CRAMS, which remain subscale. New product filings through R&D (4-5 DMFs annually) will start contributing around FY29-FY30, driving medium- to long-term growth. Incremental revenue growth will be supported by better operational efficiency, yield improvement, and capacity debottlenecking within existing facilities (around 30% spare capacity available). The company prefers investing resources in high-margin base business rather than commodity seg

Future growth expectations in earnings/operating earnings/profits/EPS?

The company does not provide explicit future earnings or EPS guidance but expresses optimism about sustaining and improving current performance. Q4 FY26 saw strong momentum with 12% QoQ revenue growth and 65% QoQ EBITDA growth, driven by the base business operating at ~26% EBITDA margin and 54% gross margins. The base business is expected to continue driving growth, focusing on increasing market share, operational efficiency, and capacity utilization in existing facilities without large capex. Incremental capex is limited to debottlenecking for high-margin products; no major greenfield expansi

Current/ Expected Orderbook/ Pending Orders?

The base business of Solara has a very healthy order book, which is encouraging for sustained performance. There is no specific quantitative figure disclosed for the current order book size. The company is focused on expanding the existing business by seeding new customers for existing products, indicating ongoing and future orders. CRAMS business remains subscale with annual revenues around INR 10-12 crores and lacks a strong order pipeline currently. New product filings (4-5 DMFs annually) are planned, but meaningful revenue impact from these is expected around FY29-FY30. Vizag fac

IN US

Sale is live|00:00:00left today

Solara Active Pharma Sciences LtdQ1 FY26Pharmaceuticals & Biotechnology

Solara Active Pharma Sciences Ltd Q1 FY26 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹570Market Cap: ₹2.1K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

Order

Yes

Capex

1 of 5 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3

→The company expects growth momentum mainly from its base business, focusing on expanding existing products and customers rather than ibuprofen or CRAMS, which remain subscale.
→New product filings through R&D (4-5 DMFs annually) will start contributing around FY29-FY30, driving medium- to long-term growth.
→Incremental revenue growth will be supported by better operational efficiency, yield improvement, and capacity debottlenecking within existing facilities (around 30% spare capacity available).
→The company prefers investing resources in high-margin base business rather than commodity segments like ibuprofen, which have shown negative returns.
→Management is hopeful to sustain and improve the recent positive quarterly performance and aims for 15-20% plus growth in the near term but is cautious about giving explicit guidance.
→Long-term strategic growth will be driven by new geographies, increased market share, and enhanced product pipeline, supported by a strong leadership team.

Margin guidance

Category 3

→The company does not provide explicit future earnings or EPS guidance but expresses optimism about sustaining and improving current performance.
→Q4 FY26 saw strong momentum with 12% QoQ revenue growth and 65% QoQ EBITDA growth, driven by the base business operating at ~26% EBITDA margin and 54% gross margins.
→The base business is expected to continue driving growth, focusing on increasing market share, operational efficiency, and capacity utilization in existing facilities without large capex.
→Incremental capex is limited to debottlenecking for high-margin products; no major greenfield expansions planned.
→R&D revival includes plans to file 4-5 new DMFs per year from FY27, with revenue impact expected by FY29-FY30.
→The company targets becoming debt-free by FY29, supporting financially stable growth.
→The ibuprofen business is generating negative EBITDA; strategic options are being evaluated with outcomes expected in the next two quarters, impacting future profit dynamics.

3 more insights locked — sign up free to unlock

Fundraise plans

→After the recently completed rights issue, there are no further plans to raise additional capital through equity or debt at this time. (Page 13)
→The company aims to become debt-free by FY '29, targeting both long-term and working capital debt elimination. (Page 13)
→No major future fundraising activities for growth or debt paydown are expected in the next 2-3 years based on current plans. (Page 13)

Order book

Yes

→The base business of Solara has a very healthy order book, which is encouraging for sustained performance.
→There is no specific quantitative figure disclosed for the current order book size.
→The company is focused on expanding the existing business by seeding new customers for existing products, indicating ongoing and future orders.
→CRAMS business remains subscale with annual revenues around INR 10-12 crores and lacks a strong order pipeline currently.
→New product filings (4-5 DMFs annually) are planned, but meaningful revenue impact from these is expected around FY29-FY30.
→Vizag facility remains mothballed; no current revenues; strategic options for this facility and ibuprofen business are under evaluation with clarity expected by H1 FY27.
→Utilization across existing facilities is around 70%, leaving approximately 30% capacity to absorb incremental orders without significant new capex.

Capex plans

→No large greenfield capex planned; focus is on utilizing existing capacity (around 30% spare capacity available).
→Incremental capex being done to debottleneck lines for high-margin products and improve cycle times.
→No big capex projects; emphasis on "smart and wise" use of existing capacity.
→No current plans for additional capital raising beyond the recent rights issue; company aims to be debt-free by FY '29.
→Vizag facility mothballed; future use under strategic evaluation (options include potentially repositioning as multipurpose or high-potent API block).
→R&D investment of about INR 25 crores annually starting FY '26, to file 4–5 new DMFs per year with commercial impact expected FY '29 onwards.
→The ibuprofen business may require strategic decisions including potential sale or technology change but no major capex planned there under current approach.

How does Solara Active Pharma Sciences Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

1Solara Active Pharma Sciences Ltd

Rev 3Mar 3

See full Pharmaceuticals & Biotechnology sector rankings

Want more stocks like Solara Active Pharma Sciences Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio